Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ONSEMBLE: Onvansertib + FOLFIRI/Bevacizumab in 2L mCRC
NCT05593328Phase 2Completed
- Sponsor
- Cardiff Oncology
- Start
- Mar 2023
- Primary completion
- Dec 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of onvansertib in metastatic colorectal cancer (mCRC), sponsored by Cardiff Oncology. Started Mar 2023; status: completed.
02
Drugs
onvansertib
03
Conditions
metastatic colorectal cancer (mCRC)
Beyond the preview
Go deeper on NCT05593328.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05593328.